Micromachine d'essais mécaniques de type traction et compression ayant une accessibilité optimisée

L'invention concerne une micromachine de traction destinée à être utilisée dans une enceinte de microscope électronique à balayage ou avec un appareil de diffraction, comportant deux mors (1) portés par deux supports, chaque mors (1) étant destiné à recevoir une extrémité d'une éprouvette mécanique (4), et des moyens pour exercer sur les supports des efforts tendant à les écarter l'un de l'autre ou à les rapprocher l'un de l'autre selon une direction longitudinale (AL), chaque mors (1) comprenant une embase (2) et une bride (3) pour fixer une extrémité (21) d'éprouvette (4) au mors (1) en l'enserrant entre la bride (3) et l'embase (2) au moyen d'au moins deux vis (12-15 ) traversant chacune la bride (3) et au moins une partie de l'embase (2), ces deux vis (12-15) étant situées de part et d'autre de l'extrémité d'éprouvette (21)

Micromachine d'essais mécaniques de type traction et compression ayant une accessibilité optimisée

L'invention concerne une micromachine de traction destinée à être utilisée dans une enceinte de microscope électronique à balayage ou avec un appareil de diffraction, comportant deux mors (1) portés par deux supports, chaque mors (1) étant destiné à recevoir une extrémité d'une éprouvette mécanique (4), et des moyens pour exercer sur les supports des efforts tendant à les écarter l'un de l'autre ou à les rapprocher l'un de l'autre selon une direction longitudinale (AL), chaque mors (1) comprenant une embase (2) et une bride (3) pour fixer une extrémité (21) d'éprouvette (4) au mors (1) en l'enserrant entre la bride (3) et l'embase (2) au moyen d'au moins deux vis (12-15 ) traversant chacune la bride (3) et au moins une partie de l'embase (2), ces deux vis (12-15) étant situées de part et d'autre de l'extrémité d'éprouvette (21)

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report

Abstract Background In clinical oncology, only a few applications have been developed using HPV as a personalized tumor marker, a lack most probably related to the limited information obtained by the classical Polymerase Chain Reaction (PCR) approach. To overcome this limitation, we have recently developed the capture-based Next-Generation Sequencing (NGS) “CaptHPV” assay, designed to provide an extensive and comprehensive molecular characterization of HPV DNA sequences associated with neoplasias, ie the sequence of the viral genome (245 genotypes), its physical state, viral load, integration site and genomic alterations at integration locus. These data correspond to highly specific tumor markers that can be used to improve diagnosis and patient’s follow-up. Case presentation We report here a case that is a straightforward and practical illustration of the power of the CaptHPV method. A patient developed successively a carcinoma of the anal canal and of the tongue. The two tumors were squamous cell carcinoma, found associated with HPV16 using PCR. In order to document a possible metastasis to the tongue from the anal cancer, we performed CaptHPV analysis on the two tumors. The analysis of the anal carcinoma found 55 viral/human hybrid reads allowing the identification of the HPV16 DNA integration in the 4q25 chromosomal band locus with a 178,808 bp deletion in the cell genome. Molecular analysis of the tongue tumor disclosed 6110 reads of HPV16, with a viral pattern strictly identical to that of the anal tumor. A total of 131 hybrid reads between HPV16 and the cell genome were found, corresponding exactly to the same locus of integration of viral DNA at the 4q25 site. The 178,808 bp genomic deletion was also found in the lingual tumor. The exact identity of HPV insertional signatures in the two tumors, demonstrates unambiguously that the tongue tumor derived from the anal cancer whereas neither histological immunophenotyping nor classical viral analysis using PCR could allow a definitive diagnosis. Conclusion Our observation indicates that the establishment of a detailed cartography of HPV DNA sequences in a tumor specimen provides crucial information for the design of specific biomarkers that can be used for diagnostic, prognostic or predictive purposes

Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03).

International audienceBACKGROUND AND PURPOSE: The aim of this study was to prospectively assess the quality of life (QOL) of patients treated by concomitant chemo radiation for locally advanced anal canal carcinoma. MATERIALS AND METHODS: We report on a subgroup of 119 patients enrolled in a 306-patient therapeutic intensification prospective trial (ACCORD 03). This trial evaluated the impact on colostomy-free survival of induction chemotherapy and/or high dose radiotherapy (factorial design 2 *2 treatment arms). QOL was assessed both before and 2 months after treatment using the EORTC QLQ-C30 questionnaire as well as a questionnaire relating to anal sphincter conservative treatment (AS-CT). RESULTS: Compared to pre-treatment scores, patients reported significant improvement in their emotional function (+8.4 points p=0.002), global health status (+5.9 points p=0.0007), as well as a decrease in insomnia (-13.8 points p<0.0001), constipation (-12.0 points p<0.0001), appetite loss (-10.3 points p<0.0001) and pain (-9.6 points p=0.0002). The AS-CT degree of satisfaction with intestinal functions score was increased (+11.2 points p<0.0001). CONCLUSION: This is the first prospective study comparing QOL of patients with advanced anal canal carcinoma, before and 2 months after conservative treatment. Two months after treatment, QOL was improved. Induction chemotherapy and/or high dose radiotherapy did not provide a negative impact on QOL

Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)

International audienc

In Regard to Perrier et al

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Impact of dosimetric parameters on local control for patients treated with three-dimensional pulsed dose-rate brachytherapy for cervical cancer

International audienceTo investigate the impact of dose-volume histograms parameters on local control of three-dimensional (3D) image-based pulsed dose-rate brachytherapy (BT).METHODS AND MATERIALS:Within a French multicentric prospective study, the data of the 110 patients treated for cervical cancer with external beam radiotherapy followed by 3D image-based and optimized pulsed dose-rate BT were analyzed. Delineation procedures were performed on magnetic resonance imaging in a minority of cases and on CT for the majority of cases, adapted from the Gynaecological Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology recommendations. Optimization procedure was left to the discretion of the treating center.RESULTS:At 2 years, local control rate reached 78%. Dose to Point A, total reference air kerma, and intermediate-risk clinical target volume (IR-CTV) V60 were predictive factors for local control (p = 0.001, p = 0.001, and p = 0.013, respectively). Patients with IR-CTV V60 <75% had a relative risk of local recurrence of 3.8 (95% confidence interval, 1.4-11.1). There was no correlation found between the high-risk clinical target volume dosimetric parameters and local control.CONCLUSIONS:This multicentric study has shown that 3D image-based BT provides a high local control rate for cervical cancer patients. The V60 for IR-CTV was identified as an important predictive factor for local control

Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial

International audienc

Radiothérapie stéréotaxique robotisée par CyberKnife®: aspects techniques et indications

National audienceEn 2006, l'Institut national du cancer a lancé un appel d'offres portant sur la radiothérapie stéréotaxique extracrânienne. Trois sites (Lille, Nancy et Nice) ont été sélectionnés pour implanter et évaluer un robot de radiothérapie, le CyberKnife®. Cette machine capable de suivre des tumeurs mobiles en temps réel ouvre de nouvelles perspectives dans le champ de la radiothérapie stéréotaxique, notamment dans sa composante extracrânienne. Les fonctionnalités de cet équipement et le coût de sa mise en oeuvre vont être évalués sur une période de deux ans sur les trois sites considérés